

Clal Insurance Enterprises Holdings Ltd
CLAL INSURANCE ENTERPRISES HOLDINGS LTD
Number in the register: 520036120

To: Israel Securities Authority To: Tel Aviv Stock Exchange Ltd. T087 (Public) Filed via MAGNA: 09/04/2026
www.isa.gov.il www.tase.co.il Reference: 2026-01-032687

Share capital status, grant of rights to purchase shares and the corporation’s securities registers and the changes therein
Regulation 31E of the Securities Regulations (Periodic and Immediate Reports), 5730 - 1970
Regulation 31(a) of the Securities Regulations (Periodic and Immediate Reports), 5730 - 1970
Regulation 31(b1) of the Securities Regulations (Periodic and Immediate Reports), 5730 - 1970
Regulation 32 of the Securities Regulations (Periodic and Immediate Reports) 5730 - 1970

Nature of the change: Conversion into shares of BONDS Series 2’
Explanation: A brief description must be provided of the nature of the change

Reference numbers of previous reports on the subject: _____, _____, _____.

1. The corporation’s securities status after the change:

Name and type of security	Security no. on the TASE	Quantity in the registered capital	Issued and paid-up capital		Quantity registered in the name of a registration company
			Quantity in last report	Current quantity	
Ordinary share, NIS 1 par value	224014	100,000,000	80,743,581	80,771,909	80,770,898
Warrant A, Plan 06/2023	1198647	0	425,957	425,957	0
Warrant A, Plan 06/2024	1208552	0	1,286,805	1,286,805	0
Warrant A, Plan 06/2025	1223080	0	130,000	130,000	0
Warrant B, Plan 06/2025	1223098	0	470,000	470,000	0
BONDS Series A	1193481	0	549,100,060	549,100,060	549,100,060
BONDS Series B	1193499	0	92,990,222.48	90,669,234.48	90,669,234.48
BONDS Series C	1201391	0	850,000,000	850,000,000	850,000,000
Clal Insurance RSU	1231869	0	8,810	8,810	0

Explanation: All of the company’s securities must be detailed, including securities not listed for trading.

2. The corporation announces that:

- ☐ On the date _____
- ☐ From date 31/03/2026 to date 03/04/2026
- ☐ A change occurred in the quantity and in the register of holders of the corporation’s securities (including rights to purchase shares) as a result of:
Description of the nature of the change Conversion into shares of BONDS Series B
Explanation: The full details must be described of the transaction or action by virtue of which the change occurred in the corporation’s securities.

Name of registered holder in respect of whom the change occurred: TASE Clearing House Ltd.

1

Type of identification number: Number in the Israeli Registrar of CompaniesIdentification number: 515736817

Nature of the change: Conversion of BONDS _____

Date of change: 03/04/2026Carried out via the TASE Clearing House: Yes Type and name of security in which the change occurred: BONDS Series B Security no. on the TASE: 1193499 Holder's balance in the security in the last report: 92,990,222.48 Holder's balance in this security after the change: 90,669,234.48 Total quantity of securities in which a decrease/increase occurred: 2,320,988 Is this a grant of rights to purchase shares No Total consideration for securities allocated: _____ TASE number of the share that will derive from exercise of the security: _____ Number of shares that will derive from full exercise/conversion of the security: _____ Total exercise premium that will be received from full exercise/conversion of the security into shares: _____ Period during which the security may be exercised: _____ From _____until _____ The securities allocated will be listed for trading: _____ The said allocation of securities is further to _____which was published on _____and its reference number is _____ ☐ The security has been fully redeemed and the consideration has been received in full. ☐ The security has been fully redeemed, but the consideration has not been received in full. ☐ Issued for an ATM program ☐ Other. _____	
Name of registered holder in respect of whom the change occurred: TASE Clearing House Ltd. Type of identification number: Number in the Israeli Registrar of CompaniesIdentification number: 515736817 Nature of the change: Conversion of BONDS _____ Date of change: 03/04/2026Carried out via the TASE Clearing House: Yes Type and name of security in which the change occurred: Ordinary share, NIS 1 par value Security no. on the TASE: 224014 Holder's balance in the security in the last report: 80,742,570 Holder's balance in this security after the change: 80,770,898 Total quantity of securities in which a decrease/increase occurred: 28,328 Is this a grant of rights to purchase shares No Total consideration for securities allocated: _____ TASE number of the share that will derive from exercise of the security: _____ Number of shares that will derive from full exercise/conversion of the security: _____ Total exercise premium that will be received from full exercise/conversion of the security into shares: _____	

Period during which the security may be exercised: _____

From _____until _____

The securities allocated will be listed for trading: _____

The said allocation of securities is further to _____which was published on _____and its reference number is _____

☐ The security has been fully redeemed and the consideration has been received in full.

☐ The security has been fully redeemed, but the consideration has not been received in full.

☐ Issued for an ATM program

☐ Other.

Explanations:

1. If the change affects more than one security, the effect of the change must be detailed in a separate line for each security.
2. Date of change – all changes of the same type, in the same security, carried out on one day, shall be summed in one line. For this purpose – a distinction must be made between changes carried out via the TASE Clearing House and changes carried out directly in the company’s books.
3. The change – for a decrease, the sign “-” must be added.
4. In all quantity fields, the number of securities must be entered and not NIS par value.

☐ A change occurred only in the corporation’s register of holders of securities **(without a change in the quantity of the corporation’s securities)** as a result of:

Description of the nature of the change _____

Explanation: The full details must be described of the transaction or action by virtue of which the change occurred in the register

1 Name of registered holder in respect of whom the change occurred: _____

Type of identification number: _____ Identification number: _____

Date of change: _____ Carried out via the TASE Clearing House: _____

Type and name of security in which the change occurred:

Security no. on the TASE: _____

Quantity of the change: _____

Holder’s balance in this security after the change: _____

3. Main details of the shareholders’ register as of the report date are as follows:

No.	Name of registered shareholder	Type of identification number	Identification number	TASE security number	Type of shares and their par value	Number of shares	Whether holds the shares as trustee
1	_____	_____	_____	_____	_____	_____	_____

4. Attached is a file of the shareholders’ register in accordance with the provisions of Section 130 of the Companies Law, 5759 - 1999 [Share090426 isa.pdf](#)

5. Attached is an updated file of the corporation’s securities registers, including the register of warrant holders and the register of BONDS holders [option090426 isa.pdf](#)

Details of the signatories authorized to sign on behalf of the corporation:

	Name of signatory	Position
1	Adv. Adi Barkan Stern	<i>Company Secretary</i> _____

Explanation: Under Regulation 5 of the Securities Regulations (Periodic and Immediate Reports) (5730 – 1970), a report submitted pursuant to these Regulations shall be signed by the persons authorized to sign on behalf of the corporation. The staff’s position on the matter can be found on the ISA’s website: [Click here](#).

The warrant plan is based on a mechanism whereby upon exercise of warrants, shares are allocated to the exercising party only in accordance with the value of the benefit (the gap between the market price and the exercise price (cashless exercise)). The calculation of the number of exercise shares for the warrants, as detailed below, was made on the theoretical maximum assumption of exercise of all the warrants into shares of the company at the company share price that was set as a cap for the value of the benefit (with respect to the 2023 plan, a cap price of NIS 113.58 per share was set, with respect to the 2024 plan, a cap price of NIS 85.75 on average per share was set, and with respect to the 2025 warrant plan, a cap price of NIS 156.80 per share was set). It is further emphasized that the foregoing is on a theoretical assumption only, since the exercise shares will actually be allocated in a quantity that will reflect the cash benefit value that will be embedded in the warrants at the time of exercise and which will be lower. Below are the exercise ratios of the warrants into shares in accordance with the foregoing: Warrant A, Plan 06/2023 0.487 Warrant A, Plan 06/2024 0.250 Warrant A and B, Plan 06/2025 0.375

Reference numbers of previous documents on the subject (the reference does not constitute inclusion by way of reference):

The corporation’s securities are listed for trading on the Tel Aviv Stock Exchange	Date of form structure update: 06/08/2024
Short name: Clal Insurance Business	
Address: Raoul Wallenberg36 , Tel Aviv, P.O. Box 370706136902 Telephone: 03-6387575 , 03-6387577Fax: 03-6397011	
Email: ClalMishpatit@clal-ins.co.il	

Previous names of reporting entity:

Name of electronic reporter: Barkan Stern Adi	Position: Company Secretary	Name of employing company: Clal Insurance Company Ltd.
Address: Raoul Wallenberg36 , Tel Aviv P.O. Box 370706136902	Telephone: 077-6387634	Fax: 03-7965879
Email: AdiBark@clal-ins.co.il		